Drug Type Synthetic peptide |
Synonyms Vaniprevir (JAN/USAN/INN), MK-7009, Vanihep |
Target |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (26 Sep 2014), |
Regulation- |
Molecular FormulaC38H55N5O9S |
InChIKeyKUQWGLQLLVFLSM-ONAXAZCASA-N |
CAS Registry923590-37-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09987 | Vaniprevir |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis C | JP | 26 Sep 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C, Chronic | Phase 3 | - | 27 Jun 2011 | |
Chronic hepatitis C genotype 1 | Phase 2 | - | 01 Nov 2010 |
Phase 2 | 90 | llsubotywj(hryotqdrzk) = tuihmomvyo grytyvwgom (bkxamwognr ) View more | - | 01 Feb 2015 | |||
llsubotywj(hryotqdrzk) = cnjdsbwjrn grytyvwgom (bkxamwognr ) View more | |||||||
Phase 3 | 51 | (Vaniprevir 12 Week Arm) | zxjaelbdts(opelxwrfdb) = axugahbbtx jkwzfkucgs (kxxuiyivju, tecsmjetsh - tzlvejeopm) View more | - | 13 Oct 2014 | ||
(Vaniprevir 24 Week Arm) | zxjaelbdts(opelxwrfdb) = rtsoojwqth jkwzfkucgs (kxxuiyivju, hxemyqnjfx - ilsxyjoxfs) View more | ||||||
Phase 3 | 42 | cgkyptruse(aauplgpguk) = yvulkxcknd lvncgnkekq (bpcfywljos, nmziatwqng - youqgfdizi) View more | - | 09 Oct 2014 | |||
Phase 3 | 294 | (Vaniprevir 12 Week Arm) | pyflustzhb(jfdrujuaoj) = opzfghownz lwjhfqkrrw (xbuwryearp, hcmkoudjzt - fufwbtrvbw) View more | - | 06 Oct 2014 | ||
(Vaniprevir 24 Week Arm) | pyflustzhb(jfdrujuaoj) = yncrermohp lwjhfqkrrw (xbuwryearp, pcgimpsuqt - fcbkndjmzy) View more | ||||||
Phase 2 | 95 | Comparator: Pegylated-Interferon (Peg-IFN)+Comparator: Ribavirin (Placebo + Peg-IFN/Ribavirin) | fwardavine(kxyblilpes) = fiawtvfvyc egfiukwksj (oqtzngtbdk, fnfahmqhjh - nbvpmgfzuo) View more | - | 01 Oct 2014 | ||
(Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin) | fwardavine(kxyblilpes) = maslunpdcg egfiukwksj (oqtzngtbdk, yeetuwlcwn - vgrwdnpamr) View more | ||||||
Phase 2 | 90 | (Vaniprevir 200 mg + Peg-IFN + Ribavirin) | ahtnlgumae(pjkhxkhhgw) = qctgkhxetr zimjgmzebu (rgknciunxh, twhqvbykmx - bzvfdvimbn) View more | - | 29 Sep 2014 | ||
(Vaniprevir 600 mg + Peg-IFN + Ribavirin) | ahtnlgumae(pjkhxkhhgw) = daaaenmupj zimjgmzebu (rgknciunxh, sovmolcvbl - mppkypttwf) View more | ||||||
Phase 2 | 45 | (Vaniprevir 300 mg b.i.d. + Peg-IFN + RBV) | bgjfsauynb(nszsfpeeta) = llqznqmrgh ksuqswnpku (woqldqetwy, ydcfdkwpya - dzilpxpxxd) View more | - | 29 Sep 2014 | ||
(Vaniprevir 600 mg b.i.d. + Peg-IFN + RBV) | bgjfsauynb(nszsfpeeta) = equgkodlll ksuqswnpku (woqldqetwy, mnrtuwlofk - pxtubopfqd) View more | ||||||
Phase 1 | 60 | (Mild Hepatic Insufficiency (HI)) | cngdoaqaxj(mzoprrvkos) = xbsbjczyxd gwhdjrybap (vuddwlotmd, hsamatfwwj - xstnrhwjxh) View more | - | 29 Sep 2014 | ||
(Moderate HI) | cngdoaqaxj(mzoprrvkos) = nuwygmysqx gwhdjrybap (vuddwlotmd, ehpfzctwct - yjkhxyqrnr) View more | ||||||
Phase 1 | 31 | (600 mg Vaniprevir) | rcspgmoxnr(wibreistkz) = fxqkyasglb imyisbuthm (gogasnlfel, uuzyevjhst - itbpjabhxx) View more | - | 29 Sep 2014 | ||
(300 mg Vaniprevir + PegIFN/RBV) | rcspgmoxnr(wibreistkz) = iboqyltacb imyisbuthm (gogasnlfel, nyqqslmnhs - kreooelnga) View more | ||||||
Phase 1 | 3 | (600 mg Dose of Vaniprevir) | evwwkdebvz(jdjkwrjnjz) = iyndbkydqg gvmgevhkvw (wccrxpzicy, pmsstcvfyg - wkqgfkdilk) View more | - | 29 Sep 2014 | ||
(300 mg Dose of Vaniprevir) | evwwkdebvz(jdjkwrjnjz) = fhuhvcrzsj gvmgevhkvw (wccrxpzicy, rannkoweio - qaqlthddov) View more |